The decision comes as Schumer is now the Senate’s #2 recipient of pharmaceutical industry campaign cash.
By David Sirota, The Lever
Senate Majority Leader Chuck Schumer (D-N.Y.) let a U.S. Senate adviser kill key parts of Democrats’ promised drug pricing legislation, as Schumer has become the Senate’s second largest recipient of pharmaceutical industry cash.

On Saturday, the Senate’s parliamentary adviser Elizabeth MacDonough — who Schumer can remove — issued a non-binding advisory opinion saying Democrats should remove provisions in their spending bill that would punish drugmakers for inflating their prices for patients in private health insurance plans. The provision could have saved $40 billion, according to one estimate.
“The exclusion of the private insurance price limits means there is little left that will reduce costs for the vast majority of Americans who receive health insurance through their private sector employer,” reported Politico.
MacDonough also advised Democrats against including a provision in their legislation to cap out-of-pocket insulin costs at $35 a month for people on private insurance plans. Democrats ultimately held a failed vote to overrule her on the insulin cap.
Recent Posts
As Security Council Stalls, There Are Other Ways to Stop U.S.-Israeli War on Iran
March 3, 2026
Take Action Now A “Uniting for Peace” resolution in the UN General Assembly can counter the Security Council’s failure to act.By Marjorie Cohn,…
States Can Block the Paramount-Warner Deal
March 3, 2026
Take Action Now But thanks to some clever maneuvering, they are already running out of time.By David Dayen, The American Prospect What started as…
Congress, Do Your Job and End This Illegal War of Aggression By The U.S. and Israel
March 2, 2026
Take Action Now Congress must assert its Constitutional authority over matters of war and peace against an out-of-control, rogue president and…
Daniel Ellsberg Speaks to Us as the War on Iran Continues
March 2, 2026
Take Action Now Ellsberg’s voice is back via a compelling new book. “Truth and Consequence,” being published this week, provides readers with his…




